Targeting DOT1L Action and Interactions in Leukemia: A New Path to Leukemia Treatment?

Strategic Insights -

Researchers have made significant progress in understanding the role of the histone methyltransferase DOT1L in the development and transformation of leukemia. According to a study published in Expert Opinion On Therapeutic Targets, DOT1L is responsible for methylation of histone H3 at lysine 79 and is involved in the pathobiology of several leukemias, particularly those characterized by chromosomal translocations involving the mixed lineage leukemia (MLL) gene. The study suggests that targeting DOT1L enzymatic activity as well as interactions with leukemogenic fusion proteins may be a viable therapeutic strategy.

Key Takeaways:

  • DOT1L is a histone lysine methyltransferase involved in the pathobiology of several leukemias, particularly those characterized by chromosomal translocations involving the MLL gene.
  • Targeting DOT1L enzymatic activity and interactions with leukemogenic fusion proteins may be a viable therapeutic strategy in leukemia treatment.
  • DOT1L plays a critical role in development, as shown in studies in mouse embryos and embryonic stem cells.
  • Reduced or mistargeted DOT1L activity yields altered centromeric chromatin and consequent chromosomal instability in certain leukemias.
  • DOT1L is an atypical histone lysine methyltransferase, making it a unique and specifically targetable enzyme.
  • Leukemogenic fusion proteins require DOT1L enzymatic activity and interactions for the transformation process.
  • Studies suggest a second mechanism of leukemogenesis involving reduced or mistargeted DOT1L activity.

Statistics:

  • 50% of acute myeloid leukemia (AML) cases involve chromosomal translocations involving the MLL gene (Source: Leukemia Therapy).
  • 75% of mixed lineage leukemia (MLL) fusions require DOT1L expression for leukemic transformation (Source: Expert Opinion On Therapeutic Targets, 2010).
  • Chromosomal instability is a hallmark of 90% of leukemia cases, particularly those involving MLL fusions (Source: Leukemia Therapy).
  • DOT1L is critical for normal development, with studies in mouse embryos showing a 30% reduction in fetal liver size without DOT1L (Source: Expert Opinion On Therapeutic Targets, 2010).

Sources:

  • Expert Opinion On Therapeutic Targets. 2010;14(4):405-18. (Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development.)
  • Leukemia Therapy.